EP4719443A1 - Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose - Google Patents
Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptoseInfo
- Publication number
- EP4719443A1 EP4719443A1 EP24816687.8A EP24816687A EP4719443A1 EP 4719443 A1 EP4719443 A1 EP 4719443A1 EP 24816687 A EP24816687 A EP 24816687A EP 4719443 A1 EP4719443 A1 EP 4719443A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- cells
- immune
- genetically modified
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363470820P | 2023-06-02 | 2023-06-02 | |
| PCT/US2024/032321 WO2024250037A1 (en) | 2023-06-02 | 2024-06-03 | Targeted immune cell therapy utilizing trail and tnf mediated apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4719443A1 true EP4719443A1 (de) | 2026-04-08 |
Family
ID=93658569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24816687.8A Pending EP4719443A1 (de) | 2023-06-02 | 2024-06-03 | Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4719443A1 (de) |
| WO (1) | WO2024250037A1 (de) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3560953T3 (pl) * | 2014-12-24 | 2024-05-13 | Autolus Limited | Komórka |
| EP3889176A1 (de) * | 2016-01-15 | 2021-10-06 | Berkeley Lights, Inc. | Verfahren zur herstellung patientenspezifischer antikrebstherapeutika und verfahren zur behandlung davon |
| WO2020247313A1 (en) * | 2019-06-01 | 2020-12-10 | Northeastern University | Microfluidic device for high-throughput screening of tumor cell adhesion and motility |
| US12577290B2 (en) * | 2021-03-04 | 2026-03-17 | Allogene Therapeutics, Inc. | FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death |
-
2024
- 2024-06-03 EP EP24816687.8A patent/EP4719443A1/de active Pending
- 2024-06-03 WO PCT/US2024/032321 patent/WO2024250037A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024250037A1 (en) | 2024-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250197471A1 (en) | Methods for the treatment of b cell malignancies using adoptive cell therapy | |
| Li et al. | KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape | |
| US12247982B2 (en) | Markers selectively deregulated in tumor-infiltrating regulatory T cells | |
| Freeman et al. | A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target | |
| CN110730908B (zh) | 表达前列腺特异性膜抗原(psma)或其修饰形式的工程化细胞及相关方法 | |
| Roussel et al. | Functional characterization of PD1+ TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade | |
| Coles et al. | CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia | |
| Parry et al. | NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma | |
| US20210190763A1 (en) | Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (car) t cells | |
| CA2954414A1 (en) | Engineered cells for adoptive cell therapy | |
| BR112020011223A2 (pt) | marcadores fenotípicos para terapia celular e mé-todos relacionados | |
| Shapiro et al. | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer | |
| Zhu et al. | CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside | |
| CN116157125A (zh) | 针对bcma的t细胞疗法与免疫调节化合物的组合 | |
| Sullivan et al. | An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells | |
| CN108778312B (zh) | 使用基于细胞的疗法治疗癌症和传染病的方法 | |
| Zhu et al. | CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation | |
| EP4719443A1 (de) | Gezielte immunzelltherapie mit trail- und tnf-vermittelter apoptose | |
| WO2020233503A1 (en) | Detection method | |
| Sullivan | Development of integrated platform of lymphocyte phenotyping, and immunotherapy validation in single cell and 3D droplet microfluidic systems | |
| RU2346279C2 (ru) | СПОСОБ ОПРЕДЕЛЕНИЯ УРОВНЯ мРНК КАТАЛИТИЧЕСКОЙ СУБЪЕДИНИЦЫ ТЕЛОМЕРАЗЫ (hTERT) | |
| Rodin | Unconventional T cells in colon adenocarcinomas | |
| RU2776823C2 (ru) | Композиции, изделия и способы, связанные с дозированием в клеточной терапии | |
| WO2026060102A1 (en) | Methodology for sorting, expansion, and transcriptomics analysis of killer t-cells | |
| WO2025196287A1 (en) | T cell lineages with early-differentiated characteristics derived from solid tumors as next generation cancer therapy and diagnostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251110 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |